Association of area deprivation and regional disparities in the treatment of T1 diabetes

November 30, 2018, Deutsches Zentrum fuer Diabetesforschung DZD
Credit: CC0 Public Domain

Treatment of the autoimmune disease type 1 diabetes in Germany depends on where the patients live in. In socio-economically weaker regions, insulin pumps and long-acting insulin analogs are used less frequently. Here, the patients have higher blood glucose levels (HbA1c) and a higher prevalence of overweight. However, the rate of severe hypoglycemia events is lower. This is the result of a study carried out by a team of researchers at the German Center for Diabetes Research (DZD) in Düsseldorf, Neuherberg and Ulm. The results have now been published in the journal Diabetes Care.

Despite significant progress in the management of type 1 diabetes in children and adolescents over the past two decades, there are regional differences in treatment. Depending on the federal state, there were differences in the use of and rapid-acting or long-acting insulin analogs, as well as (HbA1c), the prevalence of overweight and the rate of severe hypoglycemia events. But what are the reasons for these differences? Is there a correlation between the socio-economic conditions of a region and the treatment modalities of children and adolescents with type 1 diabetes? And can this be used to derive differences in treatment outcomes? Researchers at the DZD investigated these questions in the current study.

The researchers evaluated the data from the Diabetes Patient Follow-up Registry (DPV) of 29,284 patients under the age of 20 years. Among other things, they investigated how frequently pump therapy and rapid-acting or long-acting insulin analogs are used and the percentage of use of continuous tissue glucose measurement systems (CGMS). In addition to the type of treatment, treatment outcomes were also assessed. Among other things, the quality of metabolic control (assessed by the HbA1c value) and the prevalence of overweight in young type 1 diabetes patients were analyzed. "The study shows that the regional differences in treatment and treatment outcomes in young type 1 diabetes patients even exist at the district level and that these geographical differences can partly be explained by area deprivation, i.e. by a lack of material and social resources in the area measured by aggregated socio-economic indicators," said Marie Auzanneau, first author and DZD scientist at the Institute for Epidemiology and Medical Biometry, ZIBMT, at Ulm University.

For the study, the research team used the German Index of Multiple Deprivation 2010 (GIMD 2010) and its quintile subdivisions. This deprivation index was conceived by DZD scientist Werner Maier of the Institute for Health Economics and Health Care Management. The results showed that patients in the most socio-economically disadvantaged regions were less likely to receive long-acting insulin analogs (64.3 percent) than patients in the socio-economically strongest regions (80.8 percent). Continuous glucose monitoring systems (CGMS) are also less frequently used in the socio-economically weakest regions (3.4 percent of patients) than in the socio-economically strongest regions (6.3 percent of patients).

Differences can also be seen in the treatment outcomes. The average HbA1c value is 8.07 percent (65 mmol/mol) in the socio-economically weakest regions and 7.84 percent (62 mmol/mol) in the socio-economically strongest regions. In addition, patients in the most disadvantaged regions are more frequently overweight. The prevalence is 15.5 percent here and 11.8 percent in the socio-economically privileged regions. However, patients in the socio-economically weakest regions are less likely to suffer from severe hypoglycemia. The rate of severe hypoglycemia here is only 6.9 events per 100 patient years compared with 12.1 events in the socio-economically strongest areas.

"Our results suggest that the treatment outcomes of patients in socio-economically disadvantaged regions could be improved by more frequent use of pump therapy and continuous tissue glucose measurement," said DZD scientist Stefanie Lanzinger of the ZIBMT. "In order to elucidate how the individual dimensions of area deprivation are associated with treatment and outcomes in care, further studies will follow," added Joachim Rosenbauer of the German Diabetes Center in Düsseldorf.

Explore further: WHO issues recommendations for Tx intensification in T2DM

More information: Marie Auzanneau et al, Area Deprivation and Regional Disparities in Treatment and Outcome Quality of 29,284 Pediatric Patients With Type 1 Diabetes in Germany: A Cross-sectional Multicenter DPV Analysis, Diabetes Care (2018). DOI: 10.2337/dc18-0724

Related Stories

WHO issues recommendations for Tx intensification in T2DM

September 5, 2018
(HealthDay)—Recommendations have been developed by the World Health Organization for treatment intensification in type 2 diabetes. The recommendations were published online Sept. 4 in the Annals of Internal Medicine.

Can continuous glucose monitoring improve diabetes control in patients with type 1 diabetes who inject insulin

January 24, 2017
Two studies in the January 24/31 issue of JAMA find that use of a sensor implanted under the skin that continuously monitors glucose levels resulted in improved levels in patients with type 1 diabetes who inject insulin multiple ...

Insulin pumps associated with lower risk of serious complications among young patients with type 1 diabetes

October 10, 2017
Compared with insulin injections, insulin pump therapy among young patients with type 1 diabetes was associated with a lower risk of diabetic ketoacidosis and severe hypoglycemia, according to a study published by JAMA.

Human insulin as safe and effective to treat type 2 diabetes as costlier insulin analogs

June 27, 2018
Patients with Type 2 diabetes who were treated with the newer generation of insulin analog drugs did not have substantially better outcomes than those treated with less costly human insulin, according to a study by Yale School ...

Hypoglycemia link to HbA1c has declined in type 1 diabetes

October 7, 2014
The link between low average glucose blood levels and greater risk for severe hypoglycemia and hypoglycemic coma substantially declined between 1995 and 2012 in young Germans and Austrians with type 1 diabetes, according ...

In US military, white kids, officers' kids more likely to use diabetes technology

April 3, 2017
Even with equal access to healthcare in the United States military, significant disparities in caring for children with type 1 diabetes still exist, new research reports. The results of the study will be presented Monday, ...

Recommended for you

Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes

December 11, 2018
Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes.

Millions of low-risk people with diabetes may be testing their blood sugar too often

December 10, 2018
For people with Type 2 diabetes, the task of testing their blood sugar with a fingertip prick and a drop of blood on a special strip of paper becomes part of everyday life.

Very low calorie diets trialled by NHS to tackle diabetes

December 7, 2018
Hundreds of thousands of people will receive NHS help to battle obesity and type 2 diabetes under radical action set out by Simon Stevens, Chief Executive of NHS England.

Hybrid prevalence estimation: Method to improve intervention coverage estimations

December 6, 2018
LSTM's Professor Joseph Valadez is senior author on a new study published today in the Proceedings of the National Academy of Sciences, which outlines proposals for a more accurate estimator of health data.

New therapeutic avenue for type 2 diabetes

December 6, 2018
Restoring the action of insulin is one of the keys to fighting type 2 diabetes. Researchers from Inserm led by Dominique Langin at the Institute of Cardiovascular and Metabolic Diseases (Inserm/Université de Toulouse) are ...

Subtype of immune B cells can delay type 1 diabetes onset in mice

December 6, 2018
A team of researchers at Baylor College of Medicine and the University of Michigan Medical School reports today in the JCI Insight that a subset of immune B cells, known as CD19+IgM+ B cells, can delay the onset of type 1 ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.